RxDoctor Payments DataLook up a doctor →

Erin Smith

Family · Oxford, MSNPI 1205473253

Payments from drug & device makers

$13,072in general payments, 2019–2025

Across 647 payments — averaging $20.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • Pfizer$1K
  • UCB, Inc.$956
  • Novartis$690
  • AstraZeneca$578
  • Biohaven Pharmaceutical Holding Company Ltd.$431
  • plus $6K from 48 others

What the payments were for

  • Speaking & faculty fees$140%
  • Travel & lodging$2912%
  • Food & beverage$12,76798%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$13,072 in reported general payments places this provider in the 95th percentile of 3,007 family providers in Mississippi.

See all family providers in Mississippi

Medicare billing

Part B allowed, 2024
$5,233
Medicare patients
20
Services billed
422

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
AustedoDeutetrabenazine14$68,556
Nurtec OdtRimegepant Sulfate24$30,207
UbrelvyUbrogepant16$22,371
Pyridostigmine Bromide31$2,083
Levetiracetam39$2,071
Carbidopa-LevodopaCarbidopa/Levodopa77$1,882
Memantine Hcl49$1,382
Gabapentin61$1,373
Duloxetine Hcl57$1,324
Lacosamide20$1,110
Mycophenolate Mofetil17$639
Pregabalin30$544
Primidone18$505
Diclofenac Sodium15$466
RizatriptanRizatriptan Benzoate18$441

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Austedo$118$68,55614 claims
PfizerNurtec Odt$1,018$30,20724 claims
AbbVieUbrelvy$3,136$22,37116 claims
Amneal Pharmaceuticals LLCPyridostigmine Bromide, Mycophenolate Mofetil$316$2,72148 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,007 family providers in Mississippi.

Other family in Oxford

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →